Anew Biotechnology Inc. entered into a binding term sheet to acquire Alternative Investment Corporation (OTCPK:AIKO) in a reverse merger transaction on July 17, 2018. As per the term sheet, either all outstanding securities of ANEW will be exchanged for newly issued shares Alternative Investment, or all of ANEW’s assets will be transferred into a newly-formed subsidiary against newly issued shares of the common stock of Alternative Investment. ANEW shareholders shall receive an amount equal to 90% of the fully-diluted equity securities of Alternative Investment post-merger (pre-financing), and Alternative Investment shall retain post-merger (pre-financing) 10%. The target date for definitive agreement is September 17, 2018. Alternative Investment total outstanding debt of approximately $428,735 will be converted into shares of common stock of the newly formed entity at a 33.33% discount of the new entity’s valuation. The newly configured entity shall bear the name “Anew Biotechnology Inc.” If either party elects not to complete the proposed transaction, (outside of the conditions precedent) they must pay a cash penalty payment of $0.15 million to the party opposite. Upon execution of a definitive agreement, Joseph Sinkule Chief Executive Officer of ANEW, shall be appointed as Chief Executive Officer, and ANEW shall appoint all other Directors to the Board. The agreement is subject to executed definitive agreement, including satisfactory completion of due diligence within 45 days, absence of material adverse change in either party’s businesses, satisfactory completion of a contemplated capital raise, and obtaining any necessary regulatory approvals. On November 22, 2018, it was mutually agreed to postpone the execution date of the definitive agreement to occur no later than December 31, 2018.  It was further agreed that the closing of the capital raise simultaneous to the merger was to occur on or before January 17, 2019 and to close this deal and amend the agreement further to execute the agreement in Alternative Investment Corporation’s second fiscal quarter of the 2019 fiscal year. On January 13, 2019, it was mutually agreed to postpone the execution date of the definitive agreement to occur no later than February 28, 2019 and that the closing of the capital raise simultaneous to the merger was to occur on or before March 15, 2019.